The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

Drs. Goodwin and Olfson Reply

To the Editor: We were interested to learn from Drs. Ruini and Fava that a low prevalence of major depression has been found in a clinical study group of patients with panic disorder who were treated with cognitive behavior therapy. This observation is consistent with the association we reported of a lower incidence of major depression among individuals in an epidemiologic sample who received some form of treatment for panic. We are less impressed, however, with evidence linking the treatment of patients with panic disorder with antidepressants to a poorer outcome, specifically in terms of a greater risk of major depression. After a close reading of the literature, we have failed to find strong empirical support for the sensitizing effects of antidepressant medications. At least in the short term, there appears to be evidence that antidepressant medications are associated with a greater, rather than lower, incidence of depression among patients with panic disorder (1).

The work by Fava et al. (2001), suggesting that the combined use of antidepressants and benzodiazepines is associated with a worse prognosis among those with panic disorder, is based on a clinical study group and is open to selection bias. Specifically, patients with more severe or complex psychopathology may be at greater risk of developing comorbid depression and may also be more likely to be prescribed antidepressant medications.

We are in complete agreement with the sentiments expressed by Drs. Ruini and Fava that this is a topic of clinical and public health significance. Research is needed to evaluate the long-term outcome associated with the pharmacological and psychological treatment of broadly representative patient groups with panic disorder.

Reference

1. Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, Demitrack MA, Tollefson GD (The Fluoxetine Panic Disorder Study Group): Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry 1998; 155:1570-1571; erratum, 1999; 156:161Google Scholar